Roche ’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors
Roche today announced full results from the phase III HAVEN 3 study evaluating Hemlibra ® (emicizumab) prophylaxis administered every week or every two weeks in people with haemophilia A without factor VIII inhibitors and the phase III HAVEN 4 study evaluating Hemlibra prophylaxis administered every four weeks in people with haemophilia A with or without factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - May 21, 2018 Category: Pharmaceuticals Source Type: news

Follow-up phase III data showed Roche ’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death
Roche today announced follow-up data from the phase III ALEX study, showing that, as an initial treatment, Alecensa ® (alectinib) significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 57% (hazard ratio [HR]= 0.43, 95% CI: 0.32-0.58) compared to crizotinib after two years of follow-up in people with anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-sm all cell lung cancer (NSCLC), as assessed by the investigator. (Source: Roche Media News)
Source: Roche Media News - May 17, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced positive results from the Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - May 17, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress
Roche today announced that phase III results for Hemlibra ® (emicizumab) will be presented for the first time during the World Federation of Hemophilia (WFH) 2018 World Congress from 20-24 May in Glasgow, Scotland. (Source: Roche Media News)
Source: Roche Media News - May 14, 2018 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
Roche today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq ® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib. The study evaluated the combination in people with difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) whose disease progressed or who were intole rant to at least two systemic chemotherapy regimens. (Source: Roche Media News)
Source: Roche Media News - May 10, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche today announced that new data from its early and late-stage clinical studies, on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 1-5 June, in Chicago, IL, United States. More than 180 abstracts have been accepted across 13 cancer types, including two “late breakers” and 15 oral presentations. (Source: Roche Media News)
Source: Roche Media News - May 8, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - May 7, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast c ancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - April 27, 2018 Category: Pharmaceuticals Source Type: news

Roche reports a strong start in 2018
Group sales increase 6% at constant exchange rates and 5% in Swiss francs. Pharmaceuticals Division sales up 7%, driven mainly by Ocrevus and Perjeta. Diagnostics Division sales grow 5%, with increases in all business areas. (Source: Roche Media News)
Source: Roche Media News - April 26, 2018 Category: Pharmaceuticals Source Type: news

New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis
Roche announced today that new OCREVUS (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California. (Source: Roche Media News)
Source: Roche Media News - April 23, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Hemlibra in haemophilia A without inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra ® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - April 17, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline
Roche announced today that new data on its approved and investigational medicines for neurological conditions will be presented during the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California. (Source: Roche Media News)
Source: Roche Media News - April 16, 2018 Category: Pharmaceuticals Source Type: news

Roche completes acquisition of Flatiron Health
Roche today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as well as in the curation and development of real-world evidence for cancer research. With its large network of community oncology practices and academic medical centers across the US, Flatiron Health has created a technology platform designed to learn from the experience of every patient. (Source: Roche Media News)
Source: Roche Media News - April 6, 2018 Category: Pharmaceuticals Source Type: news

Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation
Roche today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co., Ltd, a member of the Roche Group, in the patent litigation case relating to Hemlibra ® (emicizumab). (Source: Roche Media News)
Source: Roche Media News - March 28, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus carboplatin and paclitaxel. (Source: Roche Media News)
Source: Roche Media News - March 26, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Roche ’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer
Roche today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - March 20, 2018 Category: Pharmaceuticals Source Type: news

Roche Annual General Meeting 2018
Roche announced today that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). (Source: Roche Media News)
Source: Roche Media News - March 13, 2018 Category: Pharmaceuticals Source Type: news

Changes to the Roche Enlarged Corporate Executive Committee
Roche today announced that John C. Reed (1958), MD, PhD, Head of Roche Pharma Research and Early Development (pRED) since 2013, has decided to leave Roche for personal reasons and will return to the United States effective 2 April 2018. (Source: Roche Media News)
Source: Roche Media News - March 8, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - February 27, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - February 27, 2018 Category: Pharmaceuticals Source Type: news

Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer
Roche and Flatiron Health, Inc. announced today that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6%. (Source: Roche Media News)
Source: Roche Media News - February 15, 2018 Category: Pharmaceuticals Source Type: news

Roche purchases shares in tender offer for Ignyta, Inc.
Roche and Ignyta, Inc. today announced that Roche ’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Ignyta, Inc. at a price of USD 27.00 per share in cash. (Source: Roche Media News)
Source: Roche Media News - February 8, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - February 6, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - February 6, 2018 Category: Pharmaceuticals Source Type: news

Roche reports good results in 2017
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and tests. I am particularly pleased with the successful launch of Ocrevus and Hemlibra and important approvals for additional indications for P erjeta, Tecentriq and Alecensa. These medicines bring substantial benefit to patients with serious diseases such as multiple sclerosis, cancer and haemophilia. Based on our strong product portfolio we are well positioned for the future.” (Source: Roche Media News)
Source: Roche Media News - February 1, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - January 26, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
Roche announced today that the European Commission (EC) has granted marketing authorisation for OCREVUS ® (ocrelizumab) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory ac tivity. (Source: Roche Media News)
Source: Roche Media News - January 12, 2018 Category: Pharmaceuticals Source Type: news

Roche commences tender offer for all shares of Ignyta, Inc. for US$ 27.00 per share in cash
Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Ignyta, Inc. at a price of US$ 27.00 per share. (Source: Roche Media News)
Source: Roche Media News - January 10, 2018 Category: Pharmaceuticals Source Type: news

Roche and GE enter partnership to develop integrated digital diagnostics platform to improve oncology and critical care treatment
Roche announced today that it has entered into a strategic, long-term partnership with GE Healthcare in order to jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patients. (Source: Roche Media News)
Source: Roche Media News - January 8, 2018 Category: Pharmaceuticals Source Type: news

Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas
Roche announced today the launch of the cobas ® Plasma Separation Card. This new solution is a stable and easy-to-use sample collection device for HIV plasma viral load testing. By providing a small amount of a patient’s blood from a fingertip, this specially designed card simplifies blood collection and sample transportation. (Source: Roche Media News)
Source: Roche Media News - January 4, 2018 Category: Pharmaceuticals Source Type: news

Roche and Ignyta reach definitive merger agreement
Roche and Ignyta, Inc. today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 billion on a fully diluted basis. This price represents a premium of 74% to Ignyta ’s closing price on 21 December 2017 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 December 2017, respectively. The merger agreement has been unanimously approved by the boards of Ignyta and Roche. (Source: Roche Media News)
Source: Roche Media News - December 22, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Media News)
Source: Roche Media News - December 21, 2017 Category: Pharmaceuticals Source Type: news